Overview of the mechanisms regulating chemokine activity and availability

Immunology Letters

Volumn 145, Issue 1-2, 2012, Pages 2-9

  Mortier, Anneleen ^a   Van Damme, Jo ^a   Proost, Paul ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Chemokine; Chemokine receptor; Glycosaminoglycan; Leukocyte migration; Posttranslational modification; Synergy

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOSAMINOGLYCAN; GUANINE NUCLEOTIDE BINDING PROTEIN; HEPARAN SULFATE; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; BIOAVAILABILITY; CELL SURFACE; CHEMOKINE GENE; CHEMOKINE RECEPTOR GENE; DOWN REGULATION; ENDOTHELIUM CELL; GENE; GENE EXPRESSION REGULATION; HUMAN; IN VIVO STUDY; LEUKOCYTE MIGRATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR GENE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84862184616     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.04.015     Document Type: Review

References (110)

1. Rot A., von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004, 22:891-928.
2. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010, 16:133-144.
3. Broxmeyer H.E. Chemokines in hematopoiesis. Curr Opin Hematol 2008, 15:49-58.
4. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010, 21:27-39.
5. Nomiyama H., Osada N., Yoshie O. The evolution of mammalian chemokine genes. Cytokine Growth Factor Rev 2010, 21:253-262.
6. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
7. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
8. Colobran R., Pujol-Borrell R., Armengol M.P., Juan M. The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. Clin Exp Immunol 2007, 148:208-217.
9. Colobran R., Adreani P., Ashhab Y., Llano A., Este J.A., Dominguez O., et al. Multiple products derived from two CCL4 loci: high incidence of a new polymorphism in HIV+ patients. J Immunol 2005, 174:5655-5664.
10. Eisman R., Surrey S., Ramachandran B., Schwartz E., Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 1990, 76:336-344.
11. Green C.J., Charles R.S., Edwards B.F., Johnson P.H. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol Cell Biol 1989, 9:1445-1451.
12. Hirashima M., Ono T., Nakao M., Nishi H., Kimura A., Nomiyama H., et al. Nucleotide sequence of the third cytokine LD78 gene and mapping of all three LD78 gene loci to human chromosome 17. DNA Seq 1992, 3:203-212.
13. Menten P., Wuyts A., Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002, 13:455-481.
14. Nakao M., Nomiyama H., Shimada K. Structures of human genes coding for cytokine LD78 and their expression. Mol Cell Biol 1990, 10:3646-3658.
15. Struyf S., Burdick M.D., Proost P., Van Damme J., Strieter R.M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004, 95:855-857.
16. Colobran R., Pedrosa E., Carretero-Iglesia L., Juan M. Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease. Clin Exp Immunol 2010, 162:41-52.
17. Colobran R., Pujol-Borrell R., Armengol M.P., Juan M. The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility. Clin Exp Immunol 2007, 150:1-12.
18. Shostakovich-Koretskaya L., Catano G., Chykarenko Z.A., He W., Gornalusse G., Mummidi S., et al. Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children. AIDS 2009, 23:679-688.
19. Menten P., Struyf S., Schutyser E., Wuyts A., De Clercq E., Schols D., et al. The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest 1999, 104:R1-R5.
20. Nathan C. Points of control in inflammation. Nature 2002, 420:846-852.
21. Ishii K.J., Koyama S., Nakagawa A., Coban C., Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008, 3:352-363.
22. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
23. Kumagai Y., Akira S. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol 2010, 125:985-992.
24. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010, 2010:672395.
25. Akira S., Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003, 85:85-95.
26. Creagh E.M., O'Neill L.A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006, 27:352-357.
27. Geijtenbeek T.B., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009, 9:465-479.
28. Petrilli V., Dostert C., Muruve D.A., Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007, 19:615-622.
29. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
30. Fan J., Heller N.M., Gorospe M., Atasoy U., Stellato C. The role of post-transcriptional regulation in chemokine gene expression in inflammation and allergy. Eur Respir J 2005, 26:933-947.
31. Hamilton T., Novotny M., Pavicic P.J., Herjan T., Hartupee J., Sun D., et al. Diversity in post-transcriptional control of neutrophil chemoattractant cytokine gene expression. Cytokine 2010, 52:116-122.
32. Kuschert G.S., Coulin F., Power C.A., Proudfoot A.E., Hubbard R.E., Hoogewerf A.J., et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999, 38:12959-12968.
33. Middleton J., Patterson A.M., Gardner L., Schmutz C., Ashton B.A. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002, 100:3853-3860.
34. Proudfoot A.E., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003, 100:1885-1890.
35. Wang L., Fuster M., Sriramarao P., Esko J.D. Endothelial heparan sulfate deficiency impairs l-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005, 6:902-910.
36. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Proudfoot A.E. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu Rev Biochem 2005, 74:385-410.
37. Johnson Z., Proudfoot A.E., Handel T.M. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005, 16:625-636.
38. Koopmann W., Ediriwickrema C., Krangel M.S. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta. J Immunol 1999, 163:2120-2127.
39. Koopmann W., Krangel M.S. Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1 alpha. J Biol Chem 1997, 272:10103-10109.
40. Graham G.J., Wilkinson P.C., Nibbs R.J., Lowe S., Kolset S.O., Parker A., et al. Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP-1alpha by mutagenesis of the proteoglycan binding site. EMBO J 1996, 15:6506-6515.
41. Martin L., Blanpain C., Garnier P., Wittamer V., Parmentier M., Vita C. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 2001, 40:6303-6318.
42. Proudfoot A.E., Fritchley S., Borlat F., Shaw J.P., Vilbois F., Zwahlen C., et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001, 276:10620-10626.
43. Lortat-Jacob H. The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr Opin Struct Biol 2009, 19:543-548.
44. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002, 2:521-528.
45. Ulvmar M.H., Hub E., Rot A. Atypical chemokine receptors. Exp Cell Res 2011, 317:556-568.
46. Graham G.J. D6 the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur J Immunol 2009, 39:342-351.
47. Naumann U., Cameroni E., Pruenster M., Mahabaleshwar H., Raz E., Zerwes H.G., et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 2010, 5:e9175.
48. Pruenster M., Mudde L., Bombosi P., Dimitrova S., Zsak M., Middleton J., et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 2009, 10:101-108.
49. Dar A., Goichberg P., Shinder V., Kalinkovich A., Kollet O., Netzer N., et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol 2005, 6:1038-1046.
50. Rot A. Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev 2005, 16:687-694.
51. D'Amico G., Frascaroli G., Bianchi G., Transidico P., Doni A., Vecchi A., et al. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol 2000, 1:387-391.
52. Ariel A., Fredman G., Sun Y.P., Kantarci A., Van Dyke T.E., Luster A.D., et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 2006, 7:1209-1216.
53. Gouwy M., Struyf S., Proost P., Van Damme J. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev 2005, 16:561-580.
54. Gouwy M., Struyf S., Noppen S., Schutyser E., Springael J.Y., Parmentier M., et al. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol Pharmacol 2008, 74:485-495.
55. Paoletti S., Petkovic V., Sebastiani S., Danelon M.G., Uguccioni M., Gerber B.O. A rich chemokine environment strongly enhances leukocyte migration and activities. Blood 2005, 105:3405-3412.
56. Ali S., O'Boyle G., Mellor P., Kirby J.A. An apparent paradox: chemokine receptor agonists can be used for anti-inflammatory therapy. Mol Immunol 2007, 44:1477-1482.
57. Richardson R.M., Pridgen B.C., Haribabu B., Snyderman R. Regulation of the human chemokine receptor CCR1. Cross-regulation by CXCR1 and CXCR2. J Biol Chem 2000, 275:9201-9208.
58. Richardson R.M., Tokunaga K., Marjoram R., Sata T., Snyderman R. Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity. Role of signal strength and receptor desensitization. J Biol Chem 2003, 278:15867-15873.
59. Weber C., Koenen R.R. Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol 2006, 27:268-273.
60. Loetscher P., Clark-Lewis I. Agonistic and antagonistic activities of chemokines. J Leukoc Biol 2001, 69:881-884.
61. Loetscher P., Pellegrino A., Gong J.H., Mattioli I., Loetscher M., Bardi G., et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001, 276:2986-2991.
62. Xanthou G., Duchesnes C.E., Williams T.J., Pease J.E. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 2003, 33:2241-2250.
63. Yu L., Cecil J., Peng S.B., Schrementi J., Kovacevic S., Paul D., et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 2006, 374:174-179.
64. De La Luz S.M., Yang F., Narazaki M., Salvucci O., Davis D., Yarchoan R., et al. Differential processing of stromal-derived factor-1 alpha and stromal-derived factor-1 beta explains functional diversity. Blood 2004, 103:2452-2459.
65. Davis D.A., Singer K.E., De La Luz S.M., Narazaki M., Yang F., Fales H.M., et al. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 2005, 105:4561-4568.
66. Laguri C., Sadir R., Rueda P., Baleux F., Gans P., Arenzana-Seisdedos F., et al. The novel CXCL12gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCR4. PLoS One 2007, 2:e1110.
67. Altenburg J.D., Broxmeyer H.E., Jin Q., Cooper S., Basu S., Alkhatib G. A naturally occurring splice variant of CXCL12/stromal cell-derived factor 1 is a potent human immunodeficiency virus type 1 inhibitor with weak chemotaxis and cell survival activities. J Virol 2007, 81:8140-8148.
68. Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adh Migr 2009, 3:243-249.
69. Rueda P., Balabanian K., Lagane B., Staropoli I., Chow K., Levoye A., et al. The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins. PLoS One 2008, 3:e2543.
70. van der Voort R., Verweij V., de Witte T.M., Lasonder E., Adema G.J., Dolstra H. An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells. J Leukoc Biol 2010, 87:1029-1039.
71. Baird J.W., Nibbs R.J., Komai-Koma M., Connolly J.A., Ottersbach K., Clark-Lewis I., et al. ESkine, a novel beta-chemokine, is differentially spliced to produce secretable and nuclear targeted isoforms. J Biol Chem 1999, 274:33496-33503.
72. Gortz A., Nibbs R.J., McLean P., Jarmin D., Lambie W., Baird J.W., et al. The chemokine ESkine/CCL27 displays novel modes of intracrine and paracrine function. J Immunol 2002, 169:1387-1394.
73. Nibbs R.J., Graham G.J. CCL27/PESKY: a novel paradigm for chemokine function. Expert Opin Biol Ther 2003, 3:15-22.
74. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4:617-629.
75. Webster N.L., Crowe S.M. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol 2006, 80:1052-1066.
76. Heutinck K.M., ten Berge I.J., Hack C.E., Hamann J., Rowshani A.T. Serine proteases of the human immune system in health and disease. Mol Immunol 2010, 47:1943-1955.
77. Pham C.T. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 2006, 6:541-550.
78. Breljak D., Gabrilovac J., Boranic M. Aminopeptidase N/CD13 and haematopoietic cells. Haema 2003, 6:453-461.
79. Lambeir A.M., Durinx C., Scharpé S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003, 40:209-294.
80. Opdenakker G., Van den Steen P.E., Dubois B., Nelissen I., Van Coillie E., Masure S., et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001, 69:851-859.
81. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
82. Kessenbrock K., Dau T., Jenne D.E. Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. J Mol Med 2011, 89:23-28.
83. Van Lint P., Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007, 82:1375-1381.
84. Proost P., Struyf S., Van Damme J. Natural post-translational modifications of chemokines. Biochem Soc Trans 2006, 34:997-1001.
85. Mortier A., Gouwy M., Van Damme J., Proost P. Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res 2011, 317:642-654.
86. Proost P., Loos T., Mortier A., Schutyser E., Gouwy M., Noppen S., et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med 2008, 205:2085-2097.
87. Mortier A., Van Damme J., Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther 2008, 120:197-217.
88. Proost P., Schutyser E., Menten P., Struyf S., Wuyts A., Opdenakker G., et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001, 98:3554-3561.
89. Proost P., Struyf S., Loos T., Gouwy M., Schutyser E., Conings R., et al. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res Ther 2006, 8:R107.
90. Proudfoot A.E., Peitsch M.C., Power C.A., Allet B., Mermod J.J., Bacon K., et al. Structure and bioactivity of recombinant human CTAP-III and NAP-2. J Protein Chem 1997, 16:37-49.
91. Van Damme J., Rampart M., Conings R., Decock B., Van Osselaer N., Willems J., et al. The neutrophil-activating proteins interleukin 8 and beta-thromboglobulin: in vitro and in vivo comparison of NH2-terminally processed forms. Eur J Immunol 1990, 20:2113-2118.
92. Walz A., Dewald B., von Tscharner V., Baggiolini M. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med 1989, 170:1745-1750.
93. Walz A., Baggiolini M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 1990, 171:449-454.
94. Iwata S., Yamaguchi N., Munakata Y., Ikushima H., Lee J.F., Hosono O., et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999, 11:417-426.
95. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997, 186:1865-1872.
96. Proost P., De Meester I., Schols D., Struyf S., Lambeir A.M., Wuyts A., et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998, 273:7222-7227.
97. Schols D., Proost P., Struyf S., Wuyts A., De Meester I., Scharpe S., et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 1998, 39:175-187.
98. Struyf S., De Meester I., Scharpé S., Lenaerts J.P., Menten P., Wang J.M., et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 1998, 28:1262-1271.
99. Proost P., Struyf S., Couvreur M., Lenaerts J.P., Conings R., Menten P., et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol 1998, 160:4034-4041.
100. Ludwig A., Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 2007, 97:694-703.
101. Loos T., Mortier A., Gouwy M., Ronsse I., Put W., Lenaerts J.P., et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008, 112:2648-2656.
102. Struyf S., Noppen S., Loos T., Mortier A., Gouwy M., Verbeke H., et al. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol 2009, 182:666-674.
103. Vossenaar E.R., Zendman A.J., van Venrooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118.
104. Klareskog L., Ronnelid J., Lundberg K., Padyukov L., Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008, 26:651-675.
105. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
106. Savino B., Borroni E.M., Torres N.M., Proost P., Struyf S., Mortier A., et al. Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence. J Biol Chem 2009, 284:26207-26215.
107. Ellyard J.I., Simson L., Bezos A., Johnston K., Freeman C., Parish C.R. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J Biol Chem 2007, 282:15238-15247.
108. Sadir R., Imberty A., Baleux F., Lortat-Jacob H. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem 2004, 279:43854-43860.
109. McQuibban G.A., Butler G.S., Gong J.H., Bendall L., Power C., Clark-Lewis I., et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001, 276:43503-43508.
110. Power C.A. Knock out models to dissect chemokine receptor function in vivo. J Immunol Methods 2003, 273:73-82.